Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.

• DOI: 10.1200/jco.2015.33.15_suppl.e19092
• Publication Date: 2019-04-19T16:25:28Z
• Authors: James Michael Ran...; Mark G. Erlander; Cecile Rose T. Vibat; Saege Hancock; Vlada Melnikova; Ezra E. W. Cohen; Scott Michael Lip...; Razelle Kurzrock; Hatim Husain
• Keywords: Minimal Residual Disease

e19092 Background: Radiographic imaging in lung adenocarcinoma patients is not always reliable and a non-tissue based approach for monitoring treatment responses or minimal residual disease desired. 15–25% of with have tumor associated KRAS mutations, these may be detected circulating (ct) DNA. The aim this study was to correlate the dynamics mutational load ctDNA clinical receiving surgical treatment, radiation, chemotherapy. Methods: In blinded biomarker 30 patients, urine samples were obtained from 7 metastatic early stage harboring G12/13 mutation tissue by CLIA laboratory testing. Following extraction urinary ctDNA, quantified using next generation sequencing-based method standardized reporting mutant copies per 105genome equivalents. Results: Of enrolled, 6 had serial collections up 3 specimens at 1-3 month intervals. Three chemotherapy, 2 detectable which tested positive 1 months prior radiologic progression. 4 definitive stereotactic body radiation therapy (SBRT) surgery cancer, now no evidence disease, any time points after surgery. suspicious progression, presentation correlated an increase Conclusions: We demonstrate feasibility chemotherapy G12/13-positive completely non-invasive sample.